Enzene Biosciences
Biosimilar developer, India. 6 development products across 6 molecules: adalimumab, bevacizumab, denosumab, pertuzumab, ranibizumab, teriparatide.
First approval in the Atlas: Jan 2021, Enzene Biosciences (INN only), teriparatide (CDSCO)
FDAproducts approved0
EMAproducts approved1
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved6
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Adalimumab | Enzene Biosciences adalimumab | · | · | · | · | Oct 2022 | · |
| Bevacizumab | Enzene Biosciences bevacizumab | · | · | · | · | Feb 2023 | · |
| Denosumab | Osqay / Enzene denosumab | · | Jan 2026 | · | · | Jul 2021 | · |
| Pertuzumab | Enzene Biosciences pertuzumab | · | · | · | · | Jun 2025 | · |
| Ranibizumab | Enzene Biosciences ranibizumab | · | · | · | · | Aug 2023 | · |
| Teriparatide | Enzene Biosciences teriparatide | · | · | · | · | Jan 2021 | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- CDSCOJan 2021Enzene Biosciences (INN only), teriparatide
- CDSCOJul 2021Enzene Biosciences (INN only), denosumab
- CDSCOOct 2022Enzene Biosciences (INN only), adalimumab
- CDSCOFeb 2023Enzene Biosciences (INN only), bevacizumab
- CDSCOAug 2023Enzene Biosciences (INN only), ranibizumab
- CDSCOJun 2025Enzene Biosciences (INN only), pertuzumab
- EMAJan 2026Osqay, denosumab
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.